Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $8.29.

VTYX has been the topic of a number of research reports. Canaccord Genuity Group lowered their price target on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Wells Fargo & Company decreased their price objective on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Finally, HC Wainwright reiterated a “neutral” rating and set a $6.00 price target on shares of Ventyx Biosciences in a research report on Tuesday, October 15th.

Institutional Trading of Ventyx Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Farallon Capital Management LLC purchased a new position in shares of Ventyx Biosciences in the first quarter worth $17,435,000. Deerfield Management Company L.P. Series C increased its position in shares of Ventyx Biosciences by 64.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after acquiring an additional 2,287,570 shares during the period. Redmile Group LLC raised its stake in shares of Ventyx Biosciences by 944.4% during the first quarter. Redmile Group LLC now owns 2,164,126 shares of the company’s stock valued at $11,903,000 after acquiring an additional 1,956,923 shares during the last quarter. First Light Asset Management LLC purchased a new stake in shares of Ventyx Biosciences during the first quarter worth about $3,437,000. Finally, Ikarian Capital LLC grew its stake in shares of Ventyx Biosciences by 8,483.8% in the first quarter. Ikarian Capital LLC now owns 507,647 shares of the company’s stock worth $2,792,000 after purchasing an additional 501,733 shares during the last quarter. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Trading Down 0.5 %

VTYX stock opened at $2.15 on Monday. The company’s 50 day moving average is $2.25 and its 200 day moving average is $2.89. The stock has a market cap of $151.94 million, a price-to-earnings ratio of -0.77 and a beta of 0.37. Ventyx Biosciences has a 1-year low of $1.79 and a 1-year high of $15.81.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.12. As a group, sell-side analysts forecast that Ventyx Biosciences will post -2.14 EPS for the current fiscal year.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.